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Abstract 
We report the case of a 46-year-old white male with confirmed Clostridium difficile 
infection for >4 weeks after fluoroquinolone therapy. The patient received two courses 
of metronidazole 500 mg three times daily (t.i.d.) during which time diarrhea resolved; 
however, symptoms recurred 14–15 days after treatment termination. He received a 
2-week course of vancomycin 125 mg four times daily, with symptoms recurring 10 days 
after treatment conclusion. The patient then received a pulsed tapering schedule of 
vancomycin with adjunctive Saccharomyces boulardii. Diarrhea recurred 12 days after 
treatment completion. He received rifaximin 400 mg t.i.d. while hospitalized for 
diarrhea-associated complications. Symptoms resolved within 24 h. The patient received 
a 4-week regimen of rifaximin 400 mg orally t.i.d. after discharge. No further episodes of 
diarrhea were reported within 6 months after treatment termination. The present case 
supports the potential benefit of rifaximin for the treatment of recurrent Clostridium 
difficile infection. 
Introduction 
Clostridium difficile infection (CDI) is a frequent cause of morbidity and mortality 
among hospitalized patients [1]. This infection typically presents with watery diarrhea 
without blood in the stool accompanied by lower abdominal pain, fever, and leukocytosis 
[2]. Symptoms usually occur after antibiotic treatment for previous illness due to the 
propensity of antibiotics to cause disruption of the gastrointestinal flora, thereby 
permitting growth of toxigenic C. difficile strains [2]. CDI has been increasing in 
prevalence and severity in recent years, perhaps due to the emergence of uncommon,  
Case Rep Gastroenterol 2010;4:404–409 
DOI: 10.1159/000320685 
Published online: 
September 28, 2010
© 2010 S. Karger AG, Basel 
ISSN 1662–0631 
www.karger.com/crg 
 
 
405
hypervirulent strains [1, 2] and a reduction in efficacy of standard CDI treatments (i.e., 
metronidazole and vancomycin) [2, 3]. Indeed, failure rates with first-line therapies of 
metronidazole and vancomycin are reported to be 22–28% and 8–19%, respectively [3]. 
Even after initial resolution of symptoms with standard antibiotic therapy, relapses of 
CDI occur in approximately 12–24% of patients [4]. This number increases dramatically 
(up to 65%) in patients with multiple instances of CDI recurrence [4]. These data 
illustrate the need for additional therapeutic options for CDI, especially for patients with 
multiple recurrences of the disease. 
Rifaximin is a nonsystemic, rifamycin-derived antibiotic that has in vitro bactericidal 
activity against C. difficile through inhibition of bacterial RNA synthesis [5]. Rifaximin is 
currently indicated for the treatment of travelers’ diarrhea caused by noninvasive 
Escherichia coli and the reduction in risk of overt hepatic encephalopathy recurrence [6] 
and has been shown to elicit no clinically relevant bacterial antibiotic resistance [7]. As 
rifaximin demonstrates in vitro activity against C. difficile [5] and does not significantly 
alter the gastrointestinal flora [7], rifaximin has been used off label for CDI [5]. An initial 
study in a hamster model of CDI showed that rifaximin, alone or in combination with 
vancomycin, increased survival compared with vehicle treatment [8]. In addition, fewer 
hamsters who received rifaximin therapy (0%) had recurrence of CDI compared with 
animals who received vancomycin (75%, p < 0.01) [8]. A subsequent case series of 
rifaximin use in humans established that rifaximin effectively prevented CDI recurrence 
when used as a ‘chaser’ in patients who had symptom resolution induced by vancomycin 
[9]. Another small, uncontrolled pilot study by Garey et al. [10] demonstrated the efficacy 
of a tapered regimen of rifaximin in resolving CDI symptoms and preventing disease 
recurrence. It remains to be seen, however, whether a standard regimen of rifaximin may 
be effective in resolving CDI. The current case report expounds on the observations of 
Garey et al. [10] and demonstrates the effective resolution and prevention of recurrence of 
CDI refractory to standard therapies by rifaximin.  
Case Report 
The 46-year-old white male patient experienced symptoms of CDI for >4 weeks after completing a 
fluoroquinolone regimen for an episode of pneumonia. He had multiple previous gastrointestinal 
problems, including chronic constipation, chronic abdominal pain, and dysphagia. His medical history 
included coronary artery disease, hypertension, seizures, and bipolar disorder. The patient’s surgical 
history included bilateral splanchnicectomy for chronic pancreatitis, 4-vessel coronary stent placement, 
and right inguinal hernia repair. 
The patient developed CDI after receiving a 2-week course of moxifloxacin 400 mg orally every day 
for pneumonia and presented with symptoms of bloating, lower abdominal cramping, and ≥10 episodes 
of watery diarrhea. Stool toxin assay results showed the presence of C. difficile, and flexible 
sigmoidoscopy indicated the presence of confluent mild colitis with yellow-white pseudomembranes in 
the sigmoid and descending colon. Subsequent treatment regimens are provided in table 1. The patient 
received metronidazole 500 mg orally 3 times daily (t.i.d.) for 2 weeks, and gastrointestinal symptoms 
abated. Fourteen days after the termination of metronidazole treatment, the patient’s abdominal and 
diarrheal symptoms returned. He again received metronidazole 500 mg t.i.d. for 2 weeks, which 
resolved the gastrointestinal symptoms, but they returned 14–15 days after treatment termination. After 
the patient’s symptoms returned a second time, he received oral vancomycin 125 mg four times daily 
(q.i.d.). His symptoms subsided during vancomycin treatment, but 10 days after treatment termination, 
he called his outpatient gastroenterologist with symptoms of recurrent diarrhea and lower abdominal 
cramping. He then received a pulsed tapering schedule of vancomycin with adjunctive probiotic therapy 
of Saccharomyces boulardii 250 mg twice daily. The schedule consisted of vancomycin 125 mg q.i.d. for 
1 week, then t.i.d. for 1 week, then every day for 1 week, then every other day for 2 weeks, and then  
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every third day for 2 weeks. Diarrheal and abdominal cramping symptoms were alleviated but returned 
12 days after the termination of vancomycin treatment. The patient experienced these symptoms for 
10 days before he was admitted to the hospital for dehydration and acute renal failure. 
On admission, the patient had a white blood cell count of 10,500 cells, which were composed of the 
following: 76% neutrophils, 16.8% lymphocytes, and 5.8% monocytes. He had elevated hemoglobin and 
hematocrit values (16.2 g/dl and 45.5%, respectively), most likely due to low total body water volume. 
Upon physical examination, the patient appeared dehydrated but had normal levels of blood urea 
nitrogen (38 mg/dl) and blood creatinine (1.4 mg/dl). Stool samples were obtained and tested positive 
for C. difficile. The patient received intravenous fluid replacement, and his abdominal and diarrheal 
symptoms were treated with oral rifaximin (XIFAXAN; Salix Pharmaceuticals, Inc., Morrisville, N.C., 
USA) 400 mg t.i.d. The diarrhea and associated gastrointestinal symptoms resolved within 24 h, and 
stool samples taken 14 days after rifaximin treatment initiation tested negative for C. difficile. The 
patient was discharged from the hospital and received a 4-week regimen of rifaximin 400 mg t.i.d. No 
adverse events were reported. During the 6-month follow-up period, he experienced no episodes of 
diarrhea. Repeat stool samples from 180 days after termination of rifaximin treatment tested negative 
for C. difficile, and flexible sigmoidoscopy revealed absence of pseudomembranes. 
Discussion 
The current standard of treatment for initial CDI includes discontinuing the inciting 
antibiotic and prescribing a regimen of either oral metronidazole or vancomycin [1]; 
however, recurrence of infection after symptoms have abated completely while on 
appropriate therapy has been reported [3]. Several studies have described various 
pharmacotherapeutic regimens to treat recurrent CDI [11–14], but there has not yet been 
one designated as standard treatment.  
Current treatment strategies for recurrent CDI include the use of metronidazole 
500 mg t.i.d. for 10 days for initially recurrent cases of CDI [2]. If symptoms recur, 
pharmacotherapy is usually switched, most often to oral vancomycin 125 mg q.i.d. 
for 10 days [2]; however, other treatment regimens have been proposed, including 
treatment with high-dose vancomycin (2 g/day) [13], tapered-dose vancomycin [14], 
and vancomycin in combination with rifampin (a rifamycin derivative) [15]. Despite the 
small sample size of these studies (n = 6–22), an available treatment algorithm for 
multirecurrent CDI (≥3 episodes) suggests that patients unresponsive to vancomycin 
500 mg/day be given a high dose of vancomycin (2 g/day) or have rifampin 600 mg/day 
added to their current vancomycin regimen [2]. If the diarrheal symptoms continue, 
colectomy may be advisable [2]. 
In the case presented, CDI recurred despite several different regimens of 
metronidazole and vancomycin, including 2 treatments with metronidazole 1,500 mg/day 
followed by low-dose vancomycin (500 mg/day) and a tapering vancomycin schedule 
combined with probiotics. Despite this therapy, diarrhea recurred, and the patient 
developed acute renal failure that required hospitalization for volume and electrolyte 
repletion. This hospitalization might have been prevented had there been another safe 
therapeutic option for recurrent CDI after metronidazole and vancomycin treatment. 
These observations support the necessity of an alternative antibiotic, such as rifaximin 
(a rifamycin derivative similar to rifampin), for the treatment of recurrent CDI.  
Rifaximin is a nonsystemic, gut-selective antibiotic that, unlike rifampin, has an 
excellent safety profile, with adverse drug interactions and overall adverse events 
comparable to those associated with placebo [5]. A previous study of 8 patients with  
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multiple CDI recurrences who received rifaximin 400–800 mg/day for 2 weeks 
immediately after vancomycin therapy demonstrated that only 1 of 8 patients (12%) 
experienced CDI recurrence [9], suggesting that rifaximin effectively prevents CDI 
after symptom resolution induced by other antibiotics (i.e., vancomycin). Further, a 
study by Garey et al. [10] showed that 5 of 6 patients (83%) had complete resolution of 
CDI after receiving rifaximin. These 5 patients received a tapered rifaximin regimen 
consisting of rifaximin 1,200 mg/day for 14 days followed by rifaximin 600 mg/day for 
14 days. Symptom resolution occurred in an average of 8 ± 5 days with no recurrence of 
symptoms during a mean follow-up period of 310 ± 145 days. The sixth patient in this 
study received rifaximin 400 mg t.i.d. for 36 days and had recurrence of C. difficile-
negative diarrhea, suggesting that rifaximin was effective for CDI resolution; however, 
long-term follow-up of this patient was not possible due to the patient’s death. 
The present case report expounds on the findings of Garey et al. [10] by demonstrating 
that rifaximin 1,200 mg/day effectively resolved CDI symptoms and achieved bacterial 
cure in a patient with recurrent CDI refractory to standard therapies. In addition, this 
case report demonstrates that rifaximin 1,200 mg/day effectively prevented recurrence of 
CDI for up to 6 months posttreatment. The rapidity of the patient’s symptom relief after 
rifaximin therapy was remarkable, given his history of recurrent diarrhea. The findings 
from the present case, along with other previously published works [9, 10], suggest that 
rifaximin may offer a promising solution to the frustrating clinical problem of recurrent 
CDI that faces many clinicians today. 
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Table 1. Treatment regimens and outcomes for a patient with recurrent CDI 
Drug Dose  Duration  Outcome 
Metronidazole  500 mg t.i.d.  2 weeks  initial resolution of diarrhea followed by 
recurrence of symptoms 14 days posttreatment 
Metronidazole  500 mg t.i.d.  2 weeks  initial resolution of diarrhea followed by 
recurrence of symptoms 14–15 days 
posttreatment 
Vancomycin  125 mg q.i.d.  2 weeks  initial resolution of diarrhea followed by 
recurrence of symptoms 10 days posttreatment 
Tapered vancomycin 
with Saccharomyces 
boulardii therapy  
(250 mg b.i.d.) 
125 mg q.i.d. 
125 mg t.i.d. 
125 mg q.d. 
125 mg q.o.d. 
125 mg dieb. tert. 
1 week 
1 week 
1 week 
2 weeks 
2 weeks 
initial resolution of diarrhea followed by 
recurrence of symptoms 12 days posttreatment 
Rifaximin  400 mg t.i.d.  4 weeks  initial resolution of diarrhea with sustained 
response up to 6 months posttreatment 
CDI = Clostridium difficile infection; b.i.d. = twice daily; dieb. tert. = every third day; q.d. = every day; 
q.i.d. = 4 times daily; q.o.d. = every other day; t.i.d. = 3 times daily. 
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